Read the findings from the ANCHOR randomized controlled trial, evaluating the efficacy and safety of combination therapy with entecavir, peginterferon alfa-2b, and GM-CSF. This important study provides robust clinical evidence on combination treatment strategies aimed at improving outcomes in chronic hepatitis B management. Read the full article: https://link.springer.com/article/10.1007/s12072-025-10977-2 #HepatitisB #HBV #CombinationTherapy #ClinicalTrials #Hepatology #AntiviralTherapy #Immunomodulation #HepatologyInternational #MedicalResearch #HealthcareProfessionals
![The Asian Pacific Association for the Study of the Liver [APASL]](https://www.apasl.info/wp-apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png)


















